publication date: Dec. 19, 2010
In this issue:
Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.
Capitol Hill: With money tight, support for 2015 goal is symbolic.
Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.
NCI selects nanotech centers for funding.
Download (PDF 490KB)
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.